The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. ‌ Shuang Li (146392)

Խորագրեր:

The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. ‌ Shuang Li (146392)

Խորագրեր:

Aggregated results for reported benefits and harms, stratified by leaflets and booklets. ‌ Maren Dreier (628959)

“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. ‌ Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. ‌ Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. ‌ Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... ‌ Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. ‌ Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. ‌ Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... ‌ Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. ‌ Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... ‌ Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. ‌ Diana M. Hendrickx (1507435)

Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. ‌ Diana M. Hendrickx (1507435)

Aerosol Capture for Coupling to Microfluidics: A Miniaturized Low-Cost Device for Size-Resolved Particle Collection ‌ Yao Xiao (227567)